Archived explainer. For the current picture see today's BLTE page.
Why Is BELITE BIO INC ADR (BLTE) Stock Down Today?
BELITE BIO INC ADR (BLTE) is down -12.16% in the latest session. Our newswire has captured 4 stories on BLTE across 4 sources in the last 36 hours, with AI sentiment reading bearish (avg 35/100).
Belite Bio (BLTE) shares fell 12.16% to $132.65 after the FDA extended the review period for its lead drug candidate, tinlarebant, by three months. The announcement triggered a sharp intraday decline, with the stock opening significantly lower and hitting a session low of $120.00 shortly after the market opened.
What Happened
The primary driver of the selloff was the FDA’s decision to extend the review timeline for the tinlarebant New Drug Application. Belite Bio, a clinical-stage drug development company focused on degenerative retinal diseases, confirmed the extension in a corporate announcement. This regulatory delay disrupted the anticipated approval timeline, causing investors to reassess the near-term catalysts for the company.
The market reaction was immediate and severe. The stock gapped down 3.3% from the prior close of $151.02, opening at $146.06. It continued to slide, reaching an intraday low of $120.00 at 9:30 AM ET before stabilizing near $133.00. The decline comes despite recent positive analyst coverage, including an Outperform rating from Leerink Partners and a price target increase to $230 by Mizuho.
What The Data Shows
Trading volume reached 0.2 million shares, representing 1.1 times the three-month daily average. The stock’s 52-week range spans from $105.88 to $200.00, and on November 20, 2026, it printed four fresh 52-week lows. The company remains unprofitable with a trailing twelve-month EPS of -2.83 and a market capitalization of $6.3 billion.
Insider activity has been notably bearish in recent months. SEC Form 4 filings show zero buys and four sells totaling $32.3 million over the last 90 days. Chief Medical Officer Hendrik Peter Scholl sold shares on November 12 and October 1, while CFO Hao-Yuan Chuang sold on September 4. The most recent insider sale occurred on November 16, 2026.
What To Watch
Investors will monitor the updated FDA review timeline for tinlarebant and any further regulatory updates. The company recently reported unaudited third quarter 2026 financial results and hosted a webcast on November 12, 2026, to discuss these figures. Future price action will likely hinge on clarity regarding the approval process and the company’s ability to maintain analyst support amidst the extended review period.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BLTE by the numbers
The headlines behind the move
Belite Bio shares slide as FDA extends tinlarebant review by three months
Belite Bio shares slide as FDA extends tinlarebant review by three months
FDA Extends Review of Belite Bio's Tinlarebant NDA, Ticker BLTE
Belite Bio Announces Extension of FDA Review Timeline for Tinlarebant NDA
SAN DIEGO, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal...
More on BLTE: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BLTE move explainers: 2026-11-20 · 2026-11-13 · 2026-11-12 · 2026-09-08 · 2026-09-04